

Apixaban for the Secondary Prevention of Thrombosis in Antiphospholipid Syndrome

Clinical and Applied Thrombosis/Hemostasis

22, 239-247

DOI: [10.1177/1076029615615960](https://doi.org/10.1177/1076029615615960)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Bipolar disorder, ischemic stroke, mitral valve vegetation and recurrent venous thrombosis due to antiphospholipid syndrome despite rivaroxaban. <i>International Journal of Cardiology</i> , 2016, 221, 383-384.	1.7	10
2	The diagnosis and management of the haematologic manifestations of lupus. <i>Journal of Autoimmunity</i> , 2016, 74, 139-160.	6.5	94
3	Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature. <i>Current Rheumatology Reports</i> , 2016, 18, 74.	4.7	76
5	Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndrome. <i>The Cochrane Library</i> , 0, , .	2.8	4
6	Direct Oral Anticoagulants in the Treatment of Venous Thromboembolic Disease. <i>Annals of Vascular Surgery</i> , 2017, 42, 337-350.	0.9	7
7	Emerging therapeutic uses of direct-acting oral anticoagulants: An evidence-based perspective. <i>Pharmacological Research</i> , 2017, 120, 206-218.	7.1	11
8	Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?. <i>Lupus</i> , 2017, 26, 1297-1303.	1.6	24
9	The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome. <i>Thrombosis Research</i> , 2017, 152, 93-97.	1.7	49
10	Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. <i>The Cochrane Library</i> , 2017, 10, CD012169.	2.8	19
11	Comment on: "The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome". <i>Thrombosis Research</i> , 2017, 157, 82-83.	1.7	5
12	Direct oral anticoagulants in hypercoagulable states. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 79-85.	2.1	28
13	Use of direct oral anticoagulants in antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1028-1039.	3.8	42
14	Venous thromboembolism controversies. <i>Disease-a-Month</i> , 2018, 64, 408-444.	1.1	3
15	Comment on: Failure of rivaroxaban to prevent thrombosis in four patients with anti-phospholipid syndrome. <i>Rheumatology</i> , 2018, 57, 938-939.	1.9	3
16	Evidence Gaps in the Era of Non-Vitamin K Oral Anticoagulants. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	25
17	Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review. <i>Blood Reviews</i> , 2018, 32, 272-279.	5.7	17
18	New and upcoming treatments in antiphospholipid syndrome: A comprehensive review. <i>Pharmacological Research</i> , 2018, 133, 108-120.	7.1	7
19	Management of Thrombotic Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 419-426.	2.7	26

#	ARTICLE	IF	CITATIONS
20	Dosing considerations in the use of the direct oral anticoagulants in the antiphospholipid syndrome. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 104-106.	1.5	9
21	Direct Oral Anticoagulant Use in Atypical Thrombosis-Related Conditions. <i>Annals of Pharmacotherapy</i> , 2018, 52, 185-197.	1.9	3
22	Protocol Modification of Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 192-192.	1.7	41
23	Anticoagulation in a patient with antiphospholipid syndrome and a mechanical heart valve. <i>Blood Coagulation and Fibrinolysis</i> , 2018, 29, 472-475.	1.0	1
25	Neurologic manifestations of antiphospholipid syndrome. <i>Lupus</i> , 2018, 27, 1404-1414.	1.6	49
26	Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. <i>The Cochrane Library</i> , 2018, 2018, CD012534.	2.8	28
27	Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. <i>Autoimmunity Reviews</i> , 2018, 17, 1011-1021.	5.8	125
28	Recurrent Thrombosis With Direct Oral Anticoagulants in Antiphospholipid Syndrome: A Systematic Literature Review and Meta-analysis. <i>Clinical Therapeutics</i> , 2019, 41, 1839-1862.	2.5	27
29	Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome. <i>Clinics in Chest Medicine</i> , 2019, 40, 519-529.	2.1	12
30	Treatment in thrombotic antiphospholipid syndrome: a review. <i>Lupus</i> , 2019, 28, 1181-1188.	1.6	8
31	Can we use NOACS in APS?. <i>Autoimmunity Reviews</i> , 2019, 18, 102408.	5.8	8
32	Lung Disease in Antiphospholipid Syndrome. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 278-294.	2.1	10
34	Comparing APLS and oranges: caution with the use of direct-acting oral anticoagulants (DOACs) instead of warfarin in the treatment of antiphospholipid syndrome (APLS). <i>BMJ Case Reports</i> , 2019, 12, e227695.	0.5	0
35	Clinical Aspects of Antiphospholipid Syndrome. , 2019, , 532-542.		0
36	Management of antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 155-161.	0.9	85
37	Treatment of antiphospholipid syndrome beyond anticoagulation. <i>Clinical Immunology</i> , 2019, 206, 53-62.	3.2	23
38	Recomendaciones de la Sociedad Española de Reumatología sobre síndrome antifosfolípido primario. Parte I: Diagnóstico, evaluación y tratamiento. <i>Reumatología Clínica</i> , 2020, 16, 71-86.	0.5	10
40	Antiphospholipid syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101463.	3.3	92

#	ARTICLE	IF	CITATIONS
41	Role of direct oral anticoagulants in patients with kidney disease. <i>Kidney International</i> , 2020, 97, 664-675.	5.2	35
42	Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study. <i>Lupus</i> , 2020, 29, 37-44.	1.6	31
43	Direct oral anticoagulants in antiphospholipid syndrome with venous thromboembolism: Impact of the European Medicines Agency guidance. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 9-12.	2.3	13
44	Recommendations of the Spanish Rheumatology Society for primary antiphospholipid syndrome. Part I: Diagnosis, evaluation and treatment. <i>Reumatología Clínica (English Edition)</i> , 2020, 16, 71-86.	0.3	0
45	Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. <i>The Cochrane Library</i> , 2020, 10, CD012169.	2.8	18
47	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020, 29, 1571-1593.	1.6	80
48	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2126-2137.	3.8	84
49	New Insights into the Use of Direct Oral Anticoagulants in Non-high Risk Thrombotic APS Patients: Literature Review and Subgroup Analysis from a Meta-analysis. <i>Current Rheumatology Reports</i> , 2020, 22, 25.	4.7	6
50	Direct oral anticoagulants versus vitamin K antagonists in antiphospholipid syndrome: A meta-analysis. <i>European Journal of Internal Medicine</i> , 2020, 79, 43-50.	2.2	16
51	Antiphospholipid syndrome. <i>Translational Research</i> , 2020, 225, 70-81.	5.0	44
52	Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS). <i>Advances in Rheumatology</i> , 2020, 60, 29.	1.7	4
53	Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management. <i>Haematologica</i> , 2020, 105, 562-572.	3.5	81
54	Antiphospholipid syndrome and direct oral anticoagulants: to the future and back again?. <i>British Journal of Haematology</i> , 2020, 189, 210-211.	2.5	1
55	An update on the management of antiphospholipid syndrome. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2091085.	2.7	26
56	Editor's Choice " European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. <i>European Journal of Vascular and Endovascular Surgery</i> , 2021, 61, 9-82.	1.5	308
57	Direct Oral Anticoagulants in Select Patients With Hypercoagulable Disorders. <i>Annals of Pharmacotherapy</i> , 2021, 55, 891-901.	1.9	7
59	Massive thrombosis and phlegmasia cerulea dolens while taking rivaroxaban: case report and review. <i>Jornal Vascular Brasileiro</i> , 2021, 20, e20200036.	0.5	1
61	Neurologic Manifestations of the Antiphospholipid Syndrome " an Update. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 41.	4.2	26

#	ARTICLE	IF	CITATIONS
62	2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. <i>Stroke</i> , 2021, 52, e364-e467.	2.0	1,123
63	Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 715878.	2.4	39
64	Direct-acting oral anticoagulants in antiphospholipid syndrome. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 58, 708-715.	1.0	4
65	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report. , 2017, , 317-338.		19
67	Cardiovascular Disease in Antiphospholipid Syndrome. <i>Current Vascular Pharmacology</i> , 2020, 18, 538-548.	1.7	6
68	Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. <i>Blood Advances</i> , 2022, 6, 1661-1670.	5.2	56
69	Management of Antiphospholipid Antibody Syndrome. , 2017, , 253-258.		0
70	Antiphospholipid Syndrome: Can the Direct Oral Anticoagulants Be Used?. , 2018, 15, .		1
72	How To Treat the Patient With Antiphospholipid Antibody Syndrome Who Needs Anticoagulation?. , 2020, 17, .		1
73	Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 67-73.	2.1	13
74	Recurrent strokes and memory loss in a patient with triple-positive antiphospholipid antibody syndrome. <i>BMJ Case Reports</i> , 2022, 15, e246104.	0.5	1
75	Neuropsychiatric Systemic Lupus Erythematosus: A Remaining Challenge. <i>Current Pharmaceutical Design</i> , 2022, 28, 881-891.	1.9	4
76	Evaluation of Apixaban in Patients With Antiphospholipid Syndrome: A Case Series and Review of Literature. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2022, 10, 232470962210998.	0.6	2
77	Neurologic Manifestations of Catastrophic Antiphospholipid Syndrome. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 589-600.	4.2	3
78	Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 437.	1.6	6
79	Update on the Diagnosis and Anticoagulant Treatment of the Antiphospholipid Syndrome. <i>European Medical Journal Rheumatology</i> , 0, , 101-111.	0.0	3
81	Cerebral venous thrombosis in patients with Sjögren's syndrome: A case report and literature review. <i>Heliyon</i> , 2023, 9, e15246.	3.2	1
83	Bilateral pulmonary embolism associated with peripheral blood eosinophilia and positive antiphospholipid antibodies in a patient with cellulitis. <i>Clinical Case Reports (discontinued)</i> , 2023, 11, .	0.5	0

#	ARTICLE	IF	CITATIONS
84	Direct-acting oral anticoagulants in antiphospholipid syndrome: A systematic review. Medicina Clínica (English Edition), 2023, 161, 65-77.	0.2	0
85	Anticoagulation Therapy for Pulmonary Embolism (PE). , 2023, , 1-30.		0